By Super Admin

Seeking Alpha / - 16 hours ago

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ --...

Seeking Alpha / - 16 hours ago

Centrus to Webcast Conference Call on November 6 at 8:30 a.m. ET

BETHESDA, Md., Oct. 15, 2025 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) will broadcast its quarterly conference call with shareholders and the financial community over the Internet on Thursday, November 6, 2025, at 8:30 a.m. ET. The Company will release its third quarter...